# The role of Xuanfei Zhisou mixture plus fluticasone propionate suspension in the treatment of variant cough in children and its effect on serum amyloid A and c-reactive protein

**Authors:** Ying Zhang, Yajun Song, Jinling Xue, Ningning Xue

PMC · DOI: 10.3389/fmed.2025.1620973 · 2025-10-22

## TL;DR

This study shows that combining Xuanfei Zhisou mixture with fluticasone propionate improves cough symptoms, lung function, and immune response in children with variant cough.

## Contribution

The novel contribution is evaluating the combined effect of Xuanfei Zhisou mixture and fluticasone propionate in treating variant cough in children.

## Key findings

- The combination therapy improved pulmonary function and immune markers compared to fluticasone alone.
- Cough symptoms and inflammatory markers were significantly reduced in the combination therapy group.
- No adverse reactions were reported in either treatment group.

## Abstract

Albeit fluticasone propionate suspension is effective in treating variant cough in children, there is limited research on the use of Xuanfei Zhisou mixture, and even fewer studies on its combination application. This study aimed to estimate the role of Xuanfei Zhisou mixture (XZM) plus fluticasone propionate suspension (FPS) in the treatment of cough variant in children.

122 children with variant cough from March 2020 to May 2023 were classified into observation therapy (XZM + FPS, n = 60) and control therapy (FPS, n = 60) using block randomization. The clinical effect, inflammatory factor, pulmonary function, peripheral eosinophil count, daytime and nighttime cough scores, immune function and untoward reactions were contrasted in two groups.

The clinical effect, Forced Vital Capacity (FVC), FEV1 (Forced Expiratory Volume)/FVC, CD3+, CD4+ as well as CD4+/CD8+ of the observation therapy were higher than control therapy. After treatment, interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α), serum amyloid A (SAA), c-reactive protein (CRP), eosinophil count as well as daytime and nighttime cough scores in observation therapy were lower than control therapy. Howbeit, there was no diversity in untoward reactions between the two groups.

Xuanfei Zhisou mixture plus FPS had conspicuous role in children with variant cough, which assisted in diminishing cough symptoms, raising pulmonary function, reduce inflammatory factor level and upgrading immune function of children.

## Linked entities

- **Proteins:** IL4 (interleukin 4)
- **Chemicals:** fluticasone propionate (PubChem CID 444036)

## Full-text entities

- **Genes:** SAA [NCBI Gene 6287], CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** cough (MESH:D003371), inflammatory (MESH:D007249)
- **Chemicals:** XZM (-), fluticasone propionate (MESH:D000068298)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12586089/full.md

---
Source: https://tomesphere.com/paper/PMC12586089